GLP-1 Receptor Agonist Therapy in Patients With Extragenital Lichen Sclerosus
JAMA Dermatology · 01.06.2026 · 162 (6) · 657
DOI: 10.1001/jamadermatol.2026.0476 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2026. Verfasst von Joshua Prenner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
This case report describes 2 patients with lichen sclerosus whose symptoms improved with glucagon-like peptide-1 receptor agonists.
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Prenner, J., Rentfro, K., Vleugels, R. A., & Shahriari, N. (2026). GLP-1 Receptor Agonist Therapy in Patients With Extragenital Lichen Sclerosus. JAMA Dermatology, 162(6), 657. https://doi.org/10.1001/jamadermatol.2026.0476
Vancouver
Prenner J, Rentfro K, Vleugels RA, Shahriari N. GLP-1 Receptor Agonist Therapy in Patients With Extragenital Lichen Sclerosus. JAMA Dermatology. 2026;162(6):657. doi:10.1001/jamadermatol.2026.0476
BibTeX
@article{Prenner2026,
author = {Prenner, Joshua and Rentfro, Kathryn and Vleugels, Ruth Ann and Shahriari, Neda},
title = {GLP-1 Receptor Agonist Therapy in Patients With Extragenital Lichen Sclerosus},
journal = {JAMA Dermatology},
year = {2026},
volume = {162},
number = {6},
pages = {657},
doi = {10.1001/jamadermatol.2026.0476}
}
EUVIMED